Optimizing a proteomics platform for urine biomarker discovery

Maryam Afkarian, Manoj Bhasin, Simon T. Dillon, Manuel C. Guerrero, Robert G. Nelson, William C. Knowler, Ravi Thadhani, Towia A. Libermann

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Biomarker discovery approaches in urine have been hindered by concerns for reproducibility and inadequate standardization of proteomics protocols. In this study, we describe an optimized quantitative proteomics strategy for urine biomarker discovery, which is applicable to fresh or long frozen samples. We used urine from healthy controls to standardize iTRAQ (isobaric tags for relative and absolute quantitation) for variation induced by protease inhibitors, starting protein and iTRAQ label quantities, protein extraction methods, and depletion of albumin and immunoglobulin G (IgG). We observed the following: (a) Absence of protease inhibitors did not affect the number or identity of the high confidence proteins. (b) Use of less than 20 μg of protein per sample led to a significant drop in the number of identified proteins. (c) Use of as little as a quarter unit of an iTRAQ label did not affect the number or identity of the identified proteins. (d) Protein extraction by methanol precipitation led to the highest protein yields and the most reproducible spectra. (e) Depletion of albumin and IgG did not increase the number of identified proteins or deepen the proteome coverage. Applying this optimized protocol to four pairs of long frozen urine samples from diabetic Pima Indians with or without nephropathy, we observed patterns suggesting segregation of cases and controls by iTRAQ spectra. We also identified several previously reported candidate biomarkers that showed trends toward differential expression, albeit not reaching statistical significance in this small sample set.

Original languageEnglish (US)
Pages (from-to)2195-2204
Number of pages10
JournalMolecular and Cellular Proteomics
Volume9
Issue number10
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

Biomarkers
Proteomics
Urine
Proteins
Protease Inhibitors
Labels
Albumins
Immunoglobulin G
Potassium Iodide
Proteome
Standardization
Methanol

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Analytical Chemistry

Cite this

Afkarian, M., Bhasin, M., Dillon, S. T., Guerrero, M. C., Nelson, R. G., Knowler, W. C., ... Libermann, T. A. (2010). Optimizing a proteomics platform for urine biomarker discovery. Molecular and Cellular Proteomics, 9(10), 2195-2204. https://doi.org/10.1074/mcp.M110.000992

Optimizing a proteomics platform for urine biomarker discovery. / Afkarian, Maryam; Bhasin, Manoj; Dillon, Simon T.; Guerrero, Manuel C.; Nelson, Robert G.; Knowler, William C.; Thadhani, Ravi; Libermann, Towia A.

In: Molecular and Cellular Proteomics, Vol. 9, No. 10, 01.10.2010, p. 2195-2204.

Research output: Contribution to journalArticle

Afkarian, M, Bhasin, M, Dillon, ST, Guerrero, MC, Nelson, RG, Knowler, WC, Thadhani, R & Libermann, TA 2010, 'Optimizing a proteomics platform for urine biomarker discovery', Molecular and Cellular Proteomics, vol. 9, no. 10, pp. 2195-2204. https://doi.org/10.1074/mcp.M110.000992
Afkarian M, Bhasin M, Dillon ST, Guerrero MC, Nelson RG, Knowler WC et al. Optimizing a proteomics platform for urine biomarker discovery. Molecular and Cellular Proteomics. 2010 Oct 1;9(10):2195-2204. https://doi.org/10.1074/mcp.M110.000992
Afkarian, Maryam ; Bhasin, Manoj ; Dillon, Simon T. ; Guerrero, Manuel C. ; Nelson, Robert G. ; Knowler, William C. ; Thadhani, Ravi ; Libermann, Towia A. / Optimizing a proteomics platform for urine biomarker discovery. In: Molecular and Cellular Proteomics. 2010 ; Vol. 9, No. 10. pp. 2195-2204.
@article{a9d88ef6510c4563be3df91f63894284,
title = "Optimizing a proteomics platform for urine biomarker discovery",
abstract = "Biomarker discovery approaches in urine have been hindered by concerns for reproducibility and inadequate standardization of proteomics protocols. In this study, we describe an optimized quantitative proteomics strategy for urine biomarker discovery, which is applicable to fresh or long frozen samples. We used urine from healthy controls to standardize iTRAQ (isobaric tags for relative and absolute quantitation) for variation induced by protease inhibitors, starting protein and iTRAQ label quantities, protein extraction methods, and depletion of albumin and immunoglobulin G (IgG). We observed the following: (a) Absence of protease inhibitors did not affect the number or identity of the high confidence proteins. (b) Use of less than 20 μg of protein per sample led to a significant drop in the number of identified proteins. (c) Use of as little as a quarter unit of an iTRAQ label did not affect the number or identity of the identified proteins. (d) Protein extraction by methanol precipitation led to the highest protein yields and the most reproducible spectra. (e) Depletion of albumin and IgG did not increase the number of identified proteins or deepen the proteome coverage. Applying this optimized protocol to four pairs of long frozen urine samples from diabetic Pima Indians with or without nephropathy, we observed patterns suggesting segregation of cases and controls by iTRAQ spectra. We also identified several previously reported candidate biomarkers that showed trends toward differential expression, albeit not reaching statistical significance in this small sample set.",
author = "Maryam Afkarian and Manoj Bhasin and Dillon, {Simon T.} and Guerrero, {Manuel C.} and Nelson, {Robert G.} and Knowler, {William C.} and Ravi Thadhani and Libermann, {Towia A.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1074/mcp.M110.000992",
language = "English (US)",
volume = "9",
pages = "2195--2204",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "10",

}

TY - JOUR

T1 - Optimizing a proteomics platform for urine biomarker discovery

AU - Afkarian, Maryam

AU - Bhasin, Manoj

AU - Dillon, Simon T.

AU - Guerrero, Manuel C.

AU - Nelson, Robert G.

AU - Knowler, William C.

AU - Thadhani, Ravi

AU - Libermann, Towia A.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Biomarker discovery approaches in urine have been hindered by concerns for reproducibility and inadequate standardization of proteomics protocols. In this study, we describe an optimized quantitative proteomics strategy for urine biomarker discovery, which is applicable to fresh or long frozen samples. We used urine from healthy controls to standardize iTRAQ (isobaric tags for relative and absolute quantitation) for variation induced by protease inhibitors, starting protein and iTRAQ label quantities, protein extraction methods, and depletion of albumin and immunoglobulin G (IgG). We observed the following: (a) Absence of protease inhibitors did not affect the number or identity of the high confidence proteins. (b) Use of less than 20 μg of protein per sample led to a significant drop in the number of identified proteins. (c) Use of as little as a quarter unit of an iTRAQ label did not affect the number or identity of the identified proteins. (d) Protein extraction by methanol precipitation led to the highest protein yields and the most reproducible spectra. (e) Depletion of albumin and IgG did not increase the number of identified proteins or deepen the proteome coverage. Applying this optimized protocol to four pairs of long frozen urine samples from diabetic Pima Indians with or without nephropathy, we observed patterns suggesting segregation of cases and controls by iTRAQ spectra. We also identified several previously reported candidate biomarkers that showed trends toward differential expression, albeit not reaching statistical significance in this small sample set.

AB - Biomarker discovery approaches in urine have been hindered by concerns for reproducibility and inadequate standardization of proteomics protocols. In this study, we describe an optimized quantitative proteomics strategy for urine biomarker discovery, which is applicable to fresh or long frozen samples. We used urine from healthy controls to standardize iTRAQ (isobaric tags for relative and absolute quantitation) for variation induced by protease inhibitors, starting protein and iTRAQ label quantities, protein extraction methods, and depletion of albumin and immunoglobulin G (IgG). We observed the following: (a) Absence of protease inhibitors did not affect the number or identity of the high confidence proteins. (b) Use of less than 20 μg of protein per sample led to a significant drop in the number of identified proteins. (c) Use of as little as a quarter unit of an iTRAQ label did not affect the number or identity of the identified proteins. (d) Protein extraction by methanol precipitation led to the highest protein yields and the most reproducible spectra. (e) Depletion of albumin and IgG did not increase the number of identified proteins or deepen the proteome coverage. Applying this optimized protocol to four pairs of long frozen urine samples from diabetic Pima Indians with or without nephropathy, we observed patterns suggesting segregation of cases and controls by iTRAQ spectra. We also identified several previously reported candidate biomarkers that showed trends toward differential expression, albeit not reaching statistical significance in this small sample set.

UR - http://www.scopus.com/inward/record.url?scp=77958002294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958002294&partnerID=8YFLogxK

U2 - 10.1074/mcp.M110.000992

DO - 10.1074/mcp.M110.000992

M3 - Article

C2 - 20511394

AN - SCOPUS:77958002294

VL - 9

SP - 2195

EP - 2204

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 10

ER -